Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium - Seite 3
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131411137/en/
The Pulse Biosciences Stock at the time of publication of the news with a fall of -2,33 % to 8,40EUR on Tradegate stock exchange (30. Januar 2024, 22:26 Uhr).
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte